SCHEMBL21270988

SCHEMBL21270988

CCc1nc(-c2ccc3c(c2)CC[C@H]3NC(=O)c2cccc(C(C)O)c2)no1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMPD1 P17405 2/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ PDE4A P27815 1/20 0.39
▸ PDE4B Q07343 1/20 0.39
▸ PDE4C Q08493 1/20 0.39
▸ PDE4D Q08499 1/20 0.39
▸ LIPG Q9Y5X9 1/20 0.39
▸ WDR5 P61964 1/20 0.39
▸ KMT2A Q03164 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ BDKRB1 P46663 1/20 0.38
▸ NPY2R P49146 1/20 0.37
▸ KCNT1 Q5JUK3 1/20 0.37
▸ ROCK2 O75116 2/20 0.37
▸ ROCK1 Q13464 2/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ CFD P00746 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21270667 0.92 SMPD1 (0.42) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL30009382 0.92 SMPD1 (0.42) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL30009518 0.91 PDE4A (0.42) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL30008522 0.91 PDE4A (0.42) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL21270500 0.91 PDE4A (0.42) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL21271009 0.91 PDE4A (0.42) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL21271285 0.91 PDE4A (0.42) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL30009179 0.91 PDE4A (0.42) SMPD1NPSR1ALDH1A1TSHRHTT
SCHEMBL21270737 0.89 BDKRB1 (0.48) PDE4APDE4BPDE4CPDE4DLMNA
SCHEMBL21270736 0.89 BDKRB1 (0.48) PDE4APDE4BPDE4CPDE4DLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2025-02-20 — — US disclosed
US-12065436-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2024-08-20 — — US disclosed
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2023-04-20 — — US disclosed
US-11472796-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2022-10-18 — — US disclosed
US-20210147399-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-05-20 — — US disclosed
US-10836755-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2020-11-17 — — US disclosed
US-10836755-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2020-11-17 — — US disclosed
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2019-08-22 — — US disclosed
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2019-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230119665-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885
US-10836755-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885
US-20210147399-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885
US-12065436-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885
US-11472796-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885
US-20190256504-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885
US-20250059173-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 SMPD1 744/4885NPSR1 3483/4885ALDH1A1 3390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback